Substituted nicotinimide inhibitors of BTK for treating cancer

US11840513B2 · kind B2 · utility

Assignee

• Guangzhou Innocare Pharma Tech Co., Ltd. · CN

Inventors

• Xiangyang Chen · Beijing, CN
• Yingxiang Gao · 安丰镇, CN
• Chong Liu · Longbeilingcun, CN
• Haihong Ni · Shanghai, CN

Key dates

• Filing date: May 25, 2022
• Grant date: Dec 12, 2023
• Expiry date: May 25, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).